[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@TTRAmyloid Avatar @TTRAmyloid Not Odd

Not Odd posts on X about $arwr, $rna, $alny, $regn the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks finance cryptocurrencies

Social topic influence $arwr #7, $rna #8, $alny #12, $regn #32, $srpt #66, $ions #4, $insm, $lily, $vrtx, $nvs

Top assets mentioned Arrowhead Research Corporation (ARWR) Avidity Biosciences, Inc. Common Stock (RNA) Alnylam Pharmaceuticals, Inc. (ALNY) Regeneron Pharmaceuticals Inc (REGN) Sarepta Therapeutics, Inc. (SRPT) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Insmed, Inc. (INSM) Vertex Protocol (VRTX) Novartis AG (NVS) Protagonist Therapeutics, Inc (PTGX) Paramount Global (PARA) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Texas Pacific Land, Corp. (TPL) Royalty Pharma plc Class A Ordinary Shares (RPRX) Dyne Therapeutics, Inc. Common Stock (DYN)

Top Social Posts #

Top posts by engagements in the last XX hours

"$arwr probably a good short. No IP company is worthless eventually"
X Link @TTRAmyloid 2025-10-06T14:47Z 1242 followers, 4442 engagements

"Anyone know the best biotech focused mutual fund that can be bought in a self directed brokerage Most of the funds are so overweight to things like $alny $insm $lily and $vrtx"
X Link @TTRAmyloid 2025-10-09T02:48Z 1243 followers, XXX engagements

"$nvs basically replaces their expiring entresto revenue with $rna acquisition for less than X years of entresto revenue"
X Link @TTRAmyloid 2025-08-14T14:07Z 1242 followers, 1174 engagements

"Another potential buyout for biotech $ptgx. Not bad. Right now the mid tier companies are being bought. This makes the remaining A tier assets like Aficamten more valuable as we get closer to 2027"
X Link @TTRAmyloid 2025-10-10T15:35Z 1242 followers, XXX engagements

"$srpt was a 10b plus mcap company with a portfolio of things that dont work. $rna has a portfolio of things that do work and a platform that an acquire can build upon in DMD. Should be at least 10b plus"
X Link @TTRAmyloid 2025-09-04T22:21Z 1242 followers, 1897 engagements

"Fuck $para I signed up to watch Dexter resurrection then they suddenly delete episodes 4-10. What a dog shit platform. #cancelparamount"
X Link @TTRAmyloid 2025-10-14T13:34Z 1242 followers, XXX engagements

"$alny has been a terrible partner for $regn. Alny took regeneron money to work on their TTR assets. Regn is getting some 4th in class c5 inhibitor for myasthenia which is worthless because now you need X months to vaccinate before you can even start treatment. They also got a bunch of phase1 collaborations which has not moved out of P1 for like X years. And whats even more humiliating is that $alny market cap is larger than $regn now. Time for m&a $regn"
X Link @TTRAmyloid 2025-09-26T23:19Z 1242 followers, 5511 engagements

"@biobrainbox this is not the same at all. What reminds me of $Mltx is $arwr. No real innovation"
X Link @TTRAmyloid 2025-10-07T16:28Z 1241 followers, XXX engagements

"$rna is a good fit for $regn. Regn can instantly plug their eyelea loe hole with DM1 and FSHD then start going after DMD in different exons . Ill take XX bil in stock for the transaction. Stock will probably go up XX bil easily once market sees it as a growth company again"
X Link @TTRAmyloid 2025-09-26T23:09Z 1243 followers, 1379 engagements

"$tpl oil royalty worth 45x earnings $rprx drug royalty thats growing XX% annual worth 8x earnings"
X Link @TTRAmyloid 2025-09-18T18:13Z 1243 followers, 1057 engagements

"I think its pretty obvious now antisense RNA is the new modality for genetic based drugs. Not gene editing or aav gene replacement. This is the next platform after antibodies. What are you gonna do $regn"
X Link @TTRAmyloid 2025-10-08T18:38Z 1243 followers, XXX engagements

"$arwr has XX% downside plozasiran is worthless due to patent infringement and they basically copy $ions on everything including their mapt. Theyre 3rd and worst in line on DM and FSHD. The sooner this fraud of company goes bankrupt then better"
X Link @TTRAmyloid 2025-09-18T15:06Z 1243 followers, 6461 engagements

"Market is reappraising $ions. $ions a true Phil Fisher stock deserves the same positive appraisal as $alny and $argx"
X Link @TTRAmyloid 2025-10-08T14:00Z 1243 followers, 1269 engagements

"@ZwerBio $rna DM1 is a phase X trial for full approval and DMD44 is 10x better than anything sarepta has fshd already showing functional benefit. So this just solidifies their lead against $dyn and especially dog crap patent infringer $arwr/$srpt"
X Link @TTRAmyloid 2025-09-29T17:12Z 1242 followers, 1998 engagements